Here’s What I Made (Finally) With My Glowforge Laser Cutter

When I lifted the lid on the Glowforge laser cutter to reveal the family portrait engraved on a wooden jigsaw puzzle, it brought a smile to my face like few other tech products I’ve used before. This simple project—enabled by a very complex machine—was a long time coming, but it was worth the wait. I … Continue reading “Here’s What I Made (Finally) With My Glowforge Laser Cutter”

Ford Buys Autonomic, TransLoc as It Rolls Toward Autonomous Future

The mobility sector’s mergers and acquisitions continue at a furious pace, the latest being Ford’s announcement this week that it bought TransLoc and Autonomic, two startups it had been partnering with as part of its efforts to get self-driving cars on the road. The terms of the deals weren’t disclosed, but one of the acquisitions … Continue reading “Ford Buys Autonomic, TransLoc as It Rolls Toward Autonomous Future”

Bio Roundup: Spark v. ICER, A Solid Revelation, T Cell Deals & More

The United States has a new Health and Human Services chief who is expected to weigh in on the country’s drug-pricing debate. But how Alex Azar, a former pharma executive at Eli Lilly (NYSE: [[ticker:LLY]]), plans to throw his weight around remains to be seen. One of the latest exhibits in the debate is an … Continue reading “Bio Roundup: Spark v. ICER, A Solid Revelation, T Cell Deals & More”

Solid Discloses Duchenne Problems in IPO & Raises Rival’s Hackles

[Updated, 1/26/18, see below] Solid Biosciences was expected to ride gene therapy’s wave of recent momentum to an IPO this week. But new revelations have clouded the offering, as the company revealed just before going public that its most advanced drug candidate has been under FDA scrutiny since mid-November. The gene therapy, SGT-001, is being … Continue reading “Solid Discloses Duchenne Problems in IPO & Raises Rival’s Hackles”

Botkeeper Tallies $4.5M Investment to Automate Accounting Tasks

Bookkeeping is time-consuming, repetitive, and boring—unless you’re into that kind of thing. Sounds like a job for a machine. Software isn’t sophisticated enough to handle all of the work involved in recording transactions and managing businesses’ finances, but money is being poured into artificial intelligence technologies aimed at shifting more of the workload from humans … Continue reading “Botkeeper Tallies $4.5M Investment to Automate Accounting Tasks”

With Medical Records Tools, Apple Wades Deeper Into Digital Health

[Updated 1/24/18 4:09 p.m. See below.] Apple said Wednesday it plans to introduce new features that will allow iPhone users to access parts of their medical records through the company’s Health app. The move could impact the interoperability of health records software and spark more competition in the health IT industry. Cupertino, CA-based Apple (NASDAQ: … Continue reading “With Medical Records Tools, Apple Wades Deeper Into Digital Health”

Boston Scientific Pumps $90M Into Heart Device Startup Millipede

Boston Scientific is infusing medical device company Millipede with $90 million, an equity investment that comes with the option to acquire the startup outright. According to the agreement, Marlborough, MA-based Boston Scientific (NYSE: [[ticker:BSX]]) must exercise its option to acquire Millipede before the startup completes its ongoing clinical trial for its heart valve repair device—as … Continue reading “Boston Scientific Pumps $90M Into Heart Device Startup Millipede”

SoftBank Continues Funding Spree, Leads $865M Round for Katerra

Katerra, a building construction startup inspired by the efficient practices of electronics manufacturing, announced today it has raised $865 million in a Series D fundraising round led by the SoftBank Vision Fund. The company was co-founded in 2015 by Michael Marks, the former CEO of contract electronics manufacturer Flextronics. Katerra has large-scale ambitions that match the … Continue reading “SoftBank Continues Funding Spree, Leads $865M Round for Katerra”

Health Analytics Firm Springbuk Closes $20M Round, Plans Hiring Spree

It’s been a great month for the Indianapolis innovation community. Indiana’s capital city made the list of 20 municipal finalists vying to become the location of Amazon’s second headquarters, and a spate of local tech startups have hit new milestones. One of those startups, Springbuk, announced last week that it has raised $20 million in … Continue reading “Health Analytics Firm Springbuk Closes $20M Round, Plans Hiring Spree”

Have $100M, Looking For Ideas: NYCEDC Begins Search For a NY Bio Campus

If you had $100 million to create an epicenter for New York biotech, what would you do with it? The New York City Economic Development Corp., a quasi-governmental agency supporting job growth in New York, has put that question to the private sector. The NYCEDC has called for proposals asking a “mission-driven organization or joint … Continue reading “Have $100M, Looking For Ideas: NYCEDC Begins Search For a NY Bio Campus”

Facebook, Amazon Snap Up Boston Cybersecurity Startups Confirm, Sqrrl

Facebook and Amazon are turning to Boston tech companies to beef up their cybersecurity capabilities. Facebook (NASDAQ: [[ticker:FB]]) has acquired Confirm.io, while Amazon (NASDAQ: [[ticker:AMZN]]) has purchased Sqrrl, according to posts on the two Boston-area security startups’ respective websites. Terms weren’t disclosed for either deal. An unspecified number of Confirm employees are joining Facebook’s local … Continue reading “Facebook, Amazon Snap Up Boston Cybersecurity Startups Confirm, Sqrrl”

Should Startups Extend the Window to Exercise Options?

Pinterest did it. Square did it. And Coinbase did it, too. These unicorns have all given departing employees more than the standard 90 days to exercise their stock options. They’ve extended the window to exercise options for employees who have at least a minimum period of service. The tech recruiting site Triplebyte urged an even … Continue reading “Should Startups Extend the Window to Exercise Options?”

Facebook Touts Countermeasures to Election Hacking: Are They Enough?

Facebook expanded its mea culpa on Monday for failing to prevent “bad actors” such as Russian entities from using the social media platform to distort democratic processes—notably the U.S. presidential election in 2016. The company unveiled another series of measures it’s taking to prevent malefactors, who hide behind false names, from spreading fake and incendiary … Continue reading “Facebook Touts Countermeasures to Election Hacking: Are They Enough?”

Hey Alexa, What’s in a Name? Actually, Let’s Call You Amazon

With “Hey Google” and “Alexa” echoing from the expo halls of Las Vegas to millions of homes, the hype around voice-controlled computing is reaching a new peak in early 2018. Voice-controlled devices are permeating our world, and this new user interface is the future of computing—or so we are told by the companies purveying it. … Continue reading “Hey Alexa, What’s in a Name? Actually, Let’s Call You Amazon”

Amazon Go Reviews: Praise for Shopping Speed, Caution Around Privacy

Whole Foods has always been on the bleeding edge of improving the efficiency of the grocery store checkout. The New York Times praised the chain a decade ago for its single-line strategy, which other retailers copied. Other trade publications have noted unique tactics Whole Foods uses in its busiest stores, like the color-coded system at … Continue reading “Amazon Go Reviews: Praise for Shopping Speed, Caution Around Privacy”

With $20B to Spend, Sanofi, Celgene Bet Big on Hemophilia, CAR-T

Two top drugmakers, Sanofi and Celgene, agreed on Monday morning to shell out more than $20 billion combined, cinching deals for hemophilia drug maker Bioverativ and cell therapy developer Juno Therapeutics. Each agreement represents an expensive, risky bet on a crowded, rapidly changing field. In one acquisition, Sanofi is buying Waltham, MA-based Bioverativ (NASDAQ: [[ticker:BIVV]]), … Continue reading “With $20B to Spend, Sanofi, Celgene Bet Big on Hemophilia, CAR-T”

Why Spark and Watchdog ICER Don’t See Eye-to-Eye on $850K Gene Therapy

The first gene therapy approved in the U.S. costs $850,000. Announcing the price on Jan. 3, its owner Spark Therapeutics held out the possibility of some relief, such as installment payments, or slim rebates if the drug, a one-time shot into each eye to reduce or reverse inherited vision loss, doesn’t work or wears off. … Continue reading “Why Spark and Watchdog ICER Don’t See Eye-to-Eye on $850K Gene Therapy”

Democratization of Automation: The Next Generation of Industrial Robotics

In the coming years, artificial intelligence will have many transformative impacts, but the one perhaps most resembling science fiction will be the rise of autonomous physical systems: real-world systems that can make decisions for themselves. Of these autonomous systems, self-driving cars have captured the most attention. But the field of manufacturing, which represents one-sixth of … Continue reading “Democratization of Automation: The Next Generation of Industrial Robotics”

After Whirlwind 2017, May Mobility Plans to Expand Driverless Fleet

May Mobility, the autonomous vehicle startup based in Ann Arbor, MI, had an action-packed 2017. The company launched in January, completed a stint in the Y Combinator accelerator over the summer, put driverless shuttles on downtown Detroit streets through a small pilot program in October, and raised more than $11 million over the course of … Continue reading “After Whirlwind 2017, May Mobility Plans to Expand Driverless Fleet”

Q&A: Dell Med’s DeSalvo Talks Social Health Startups, Data Ownership

Karen DeSalvo has experience working in the public sector, but she’s hardly what you’d call a government bureaucrat. DeSalvo, who is trained as a physician, served as the National Coordinator for Health Information Technology from 2014 to 2016 under President Barack Obama. During some of the time she headed the ONC, as the office is … Continue reading “Q&A: Dell Med’s DeSalvo Talks Social Health Startups, Data Ownership”

UTA Using Robots, Shakespeare to Study Ways to Address Loneliness

Dallas—In healthcare, robots are being created to help with tasks like disinfecting hospital rooms or alerting patients when it’s time to take medications. A study at the Emotional Robotics Living Lab at the University of Texas at Arlington is even exploring how human-robot connection can help fight depression. “We are looking at robots that would be … Continue reading “UTA Using Robots, Shakespeare to Study Ways to Address Loneliness”

Bio Roundup: Spark’s Road Ahead, Juno Rumors, Merck’s Big Day & More

The most overblown health story of the week was President Trump’s health exam. America learned Trump is in perfect health and has “great genes.” He takes Propecia. He doesn’t have heart problems, had a perfect cognitive test score, and is one pound shy of obese. This scintillating information led to a new social media phenomenon, the … Continue reading “Bio Roundup: Spark’s Road Ahead, Juno Rumors, Merck’s Big Day & More”

Tougher “Immigration” Policies On Foreign Tech Crossing U.S. Border

It’s not only people from other countries that are struggling harder to get into the United States these days, it seems. Technology from foreign nations may also be subject to stricter “immigration” rules. The national origins of tech devices and services wasn’t a front-burner question—at least for the general public—until the issue came up at … Continue reading “Tougher “Immigration” Policies On Foreign Tech Crossing U.S. Border”

Absences, Surprises in Amazon’s Final List of 20 Cities for HQ2

And then there were 20. Amazon has winnowed down the field of 238 submissions from communities around North America vying to host a second headquarters (HQ2) of the Seattle-based tech giant. Most large cities with existing or emerging tech hubs appear on the list, from Austin, TX, and Boston, MA, to Washington, DC, and Toronto, … Continue reading “Absences, Surprises in Amazon’s Final List of 20 Cities for HQ2”

Accomplice Reloads With $205M Fund After Makeover

Accomplice, one of the Boston area’s prominent early-stage venture firms, has restocked its dry powder to invest in tech startups. Accomplice raised $205 million for its second fund, according to a spokesperson. The firm announced the new fund in a blog post Thursday. Partner Jeff Fagnan (pictured) declined to comment further. The fund marks a … Continue reading “Accomplice Reloads With $205M Fund After Makeover”

Pandion Raises $58M to Bring Cancer-Fighting Tactics to Immune Disorders

Many drugs for inflammatory and autoimmune disorders work by suppressing the immune system, an approach that puts patients at risk of infection among other side effects. Pandion Therapeutics is developing antibody drugs that it says could instead work with the immune system, potentially offering a safer, more targeted treatment. The Cambridge, MA, biotech has now … Continue reading “Pandion Raises $58M to Bring Cancer-Fighting Tactics to Immune Disorders”

Advancing A.I. for Business: Google Unveils Tools, Indico Nabs $4M

Tech companies continue to develop software tools and services aimed at unlocking the potential benefits of artificial intelligence for all businesses, regardless of whether or not they have skilled data scientists on staff. Two of the latest examples come from a startup, Boston-based Indico, and a tech giant, Google. Today, Indico announced it pulled in … Continue reading “Advancing A.I. for Business: Google Unveils Tools, Indico Nabs $4M”

In “Age of Amazon,” All Retailers Are Tech Companies, Even Walmart

Technology took center stage this week as the nation’s retailers made their annual pilgrimage to New York. At the National Retail Federation’s three-day conference, which ended Tuesday, the discussion centered on both the disruptive effects and potential promise of e-commerce technologies. Kate Ancketill, the CEO of GDR Creative Intelligence, a retail trends consultancy, said retailers … Continue reading “In “Age of Amazon,” All Retailers Are Tech Companies, Even Walmart”

CircleCI Nabs $31M to Enhance DevOps Platform With Automation Tools

CircleCI, which offers tools for companies seeking to speed up the process of developing their own software, announced today that it has raised $31 million in a Series C fundraising round. The San Francisco-based company, founded in 2011, offers one of the software development platforms that provide frequent, automated tests of the interim versions of … Continue reading “CircleCI Nabs $31M to Enhance DevOps Platform With Automation Tools”

Three Takes on How Tech Can Rebuild Trust in 2018

Rounding out our series of perspectives and prognostications for the new year, we asked people in Xconomy’s network about trust in the tech industry. Specifically, if you think public perception about the tech industry took a turn for the worse in 2017, what should the industry do to rebuild trust in 2018? Here are responses … Continue reading “Three Takes on How Tech Can Rebuild Trust in 2018”

Eiger Bio’s Hypertension Drug Flunks Phase 2 Trial, Shares Tumble

An Eiger BioPharmaceuticals drug being tested for the treatment of pulmonary arterial hypertension has failed a mid-stage study, and the drug developer says it will stop work on the compound for that condition. News of the clinical trial failure cut the value of shares in Palo Alto, CA, based Eiger (NASDAQ: [[ticker:EIGR]]) nearly in half. … Continue reading “Eiger Bio’s Hypertension Drug Flunks Phase 2 Trial, Shares Tumble”

Google Launches a MOOC to Train Entry-Level IT Support Staffers

Big tech companies like Google are facing heat for developing disruptive technologies that can make traditional jobs obsolete. But at the same time, the tech industry is growing fast, and is eager to recruit workers outside the sector to fill entry-level jobs that often go begging, a Google executive says. Google is betting on online … Continue reading “Google Launches a MOOC to Train Entry-Level IT Support Staffers”

Merck Is Latest to Tout Success as Lung Cancer Drug Combos Plow Forward

This morning has brought another positive development in the rapidly changing treatment landscape for lung cancer. Merck reported that a combination regimen utilizing its immunotherapy drug, pembrolizumab (Keytruda), has succeeded in a confirmational Phase 3 study. Merck (NYSE: [[ticker:MRK]]) said that a trial in which 614 patients just diagnosed with non-small cell lung cancer got … Continue reading “Merck Is Latest to Tout Success as Lung Cancer Drug Combos Plow Forward”

A.I. Could Be Double-Edged Sword for Cybersecurity Industry in 2018

It’s no secret that artificial intelligence is becoming increasingly influential in cybersecurity—on both sides of the battlefield. And while it’s no secret, it should also be no surprise. Although, in many ways, A.I. is still in its infancy, with nearly every industry investing in the space and many companies already benefiting from automation and business … Continue reading “A.I. Could Be Double-Edged Sword for Cybersecurity Industry in 2018”

Boston E-Commerce Data Firm True Fit Snags $55M in New Funds

True Fit, a Boston-area startup that is creating “a genome for apparel and footwear,” announced this morning a Series C investment of $55 million. Georgian Partners led the funding round with participation from existing investors Jump Capital, Signal Peak Ventures, and Intel Capital, along with new investor Cross Creek Capital. “We’ve built a preference map … Continue reading “Boston E-Commerce Data Firm True Fit Snags $55M in New Funds”

Why Human Extinction Needs a Marketing Department

Experts at Oxford University and elsewhere have estimated that the risk of a global human extinction event this century—or at least of an event that wipes out 10 percent or more of the world’s population— is around 1 in 10. The most probable culprits sending us the way of the dinosaur are mostly anthropogenic risks, … Continue reading “Why Human Extinction Needs a Marketing Department”

OrphoMed Names Mark Sostek Chief Medical Officer

Mark Sostek is joining San Francisco-based drug developer OrphoMed as chief medical officer. Sostek most recently worked at Pfizer (NYSE: [[ticker:PFE]]) in its inflammation and immunology research unit. Before that, he was global clinical leader for gastrointestinal programs at AstraZeneca (NYSE: [[ticker:AZN]]). OrphoMed’s lead drug candidate, ORP-101, is in early-stage clinical testing for irritable bowel … Continue reading “OrphoMed Names Mark Sostek Chief Medical Officer”

SkySpecs Snags $8M to Expand Drone-Powered Turbine Inspection Service

Drone startup SkySpecs announced this week that it has raised an $8 million Series B funding round. The investment in the Ann Arbor, MI-based company was co-led by Germany’s Statkraft Ventures, the Capital Midwest Fund, and UL Ventures, and also included contributions from returning investors such as Huron River Ventures and Venture Investors. A lot … Continue reading “SkySpecs Snags $8M to Expand Drone-Powered Turbine Inspection Service”

Spark CEO Marrazzo on Gene Therapy Pricing & Paving the Way for the Field

[Updated, 1/13/17, 11:15 a.m. ET]  After decades of research and scientific ups and downs, the first U.S. gene therapy, a single, long-lasting treatment called voretigene neparvovec (Luxturna) for rare, inherited blindness, is now on the market. But the commercial challenge facing its developer, Spark Therapeutics, is daunting. Can Spark lead the way in showing that … Continue reading “Spark CEO Marrazzo on Gene Therapy Pricing & Paving the Way for the Field”

CRISPR Recovery? “Furor” Briefly Snips $500M From Companies’ Values

Is the J.P. Morgan CRISPR rollercoaster ride over? As rain fell heavily in San Francisco Monday, the first day of the massive healthcare conference, biotech stocks did, too. At least three of the companies getting drenched could blame a research paper that came out the previous Friday, January 5, after the markets closed. In fact, … Continue reading “CRISPR Recovery? “Furor” Briefly Snips $500M From Companies’ Values”

Bio Roundup: #JPM18, Axovant’s Fall, CRISPR Caveat, Impact M&A & More

Have you gotten your flu shot yet this year? This winter’s flu season is shaping up to be a particularly nasty one and the Centers for Disease Control and Prevention this week upped its tally of states reporting widespread flu activity to 46. Flu awareness was top of mind at the J.P. Morgan Healthcare Conference … Continue reading “Bio Roundup: #JPM18, Axovant’s Fall, CRISPR Caveat, Impact M&A & More”

E-Commerce Firm Black Rifle Coffee Has Expansion in Its Sights

There wasn’t a lot that Evan Hafer could control on his half-dozen deployments to Iraq and Afghanistan as a Green Beret and CIA contractor. But the one thing he could do something about was the terrible coffee. “I started roasting my own coffee and taking it with me overseas,” he says. “I set up a … Continue reading “E-Commerce Firm Black Rifle Coffee Has Expansion in Its Sights”

Notes From the JPM ’18 Vortex: Gene Therapy’s Reckoning and Lonely Cabs

The annual J.P. Morgan Healthcare conference in San Francisco winds down today, meaning the remaining stragglers are either presenting to half-empty rooms or headed back to colder climes. Compared to a 2017 full of scientific milestones—FDA approvals of gene and cell therapies, a clinical victory for RNA interference, and more—the meeting itself was rather dull. … Continue reading “Notes From the JPM ’18 Vortex: Gene Therapy’s Reckoning and Lonely Cabs”

Toyota, Ford, Aptiv, Baidu Lead Crowd Pushing Mobility at CES

In the past, the tech conference CES has primarily highlighted consumer electronics and other cool gadgets, but as automakers continue their quest to be taken seriously by the tech industry, the Las Vegas show held every January has increasingly become the venue of choice for car companies that want to show off their latest autonomous … Continue reading “Toyota, Ford, Aptiv, Baidu Lead Crowd Pushing Mobility at CES”

Loving LTE or Tossing the Smartphone: Tech Leaders Share New Habits

We asked people around the Xconomy network whether their personal patterns of technology usage changed much in response to something that happened in 2017, as part of our series of perspectives and predictions marking the start of a new year. Here are answers from Ben Gilbert, co-founder of Pioneer Square Labs in Seattle and interim … Continue reading “Loving LTE or Tossing the Smartphone: Tech Leaders Share New Habits”

BioClin Therapeutics Adds Gilead’s Steve Abella to Executive Team

Esteban (Steve) Abella has been appointed chief medical officer of San Ramon, CA-based BioClin Therapeutics. Abella most recently worked at Gilead Sciences (NASDAQ: [[ticker:GILD]]), where he was a senior director leading the company’s non-Hodgkin lymphoma and leukemia efforts. BioClin also named Graeme Currie to the chief operating officer post. Currie’s experience includes senior leadership positions … Continue reading “BioClin Therapeutics Adds Gilead’s Steve Abella to Executive Team”

As VC Moves Downstream, Spearhead Seeds New Angel Investors

The U.S. venture capital industry just capped off one of its biggest years ever. But look closer, and the current funding environment could spell trouble for the next wave of high-tech startups. The $84.2 billion invested in 2017 is a level of VC funding unseen since the dot-com era of the early 2000s, according to … Continue reading “As VC Moves Downstream, Spearhead Seeds New Angel Investors”

Blockchain and Cryptocurrencies: ScaleVP Comments From the Sidelines

Just because an investor isn’t putting money into blockchain technologies or cryptocurrencies yet, it doesn’t mean they’re not watching these emerging phenomena with interest. Andy Vitus, a partner at Silicon Valley venture capital firm Scale Venture Partners, has been keeping his eye on the potential uses of the blockchain, which is best known as the … Continue reading “Blockchain and Cryptocurrencies: ScaleVP Comments From the Sidelines”

After Boom Years, Starburst and Podium May Signal Big Data’s Future

It seems like ancient history now, but “big data” was once a hot field with startups, investors, and big companies all buzzing with hype. Then the tech industry moved on, and marketers crowned data science and machine learning the Next Big Things (at least until blockchain takes over). Of course, big data never really went … Continue reading “After Boom Years, Starburst and Podium May Signal Big Data’s Future”